Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Set to Delist Valentis Stock for Low Market Cap; Firm to Appeal

NEW YORK, Aug. 28 - Valentis today said the Nasdaq exchange has threatened to delist its stock for failing to hold its market capitalization above $50 million.

 

Valentis said it received a letter from the Nasdaq on Aug. 22 that said the stock will be delisted from the exchange on Aug. 30 unless the company requests an appeal hearing.Valentis said it requested a hearing and will appear before a Nasdaq listing-qualifications panel to discuss how it plans to set itself straight. The meeting will likely take place within 45 days.

 

The company, maker of the GeneMedicine and GeneSwitch DNA vaccine platforms, stressed that obtaining a hearing does not guarantee a stay of delisting.

 

Shares in Valentis closed down $.14 at $.60 yesterday. Valentis' market cap is $21.0 million.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.